The Pfizer/BioNTech was available first so there is more data, but the Oxford/AstraZeneca was mostly used in the older age group. The study was not set up to look at any differences between the two. The numbers were very small and there was uncertainty over their significance, said the researchers. That rose to more than 85% after the second dose. It is an important point but we cant at the moment say anything about that, he said.
Pfizer/ BioNTech is a nbiggerty thing
( z0 thing :ARG1-of ( z1 have-degree :ARG2 ( z2 big ) :ARG3 ( z3 more ) ) :domain ( z4 slash :op ( z5 company :name ( z6 name :op "Pfizer" ) ) :op ( z7 company :name ( z8 name :op "BioNTech" ) ) ) )
(z0 / thing
    :ARG1-of (z1 / have-degree-91
                 :ARG2 (z2 / big)
                 :ARG3 (z3 / more))
    :domain (z4 / slash
                :op1 (z5 / company
                         :name (z6 / name
                                   :op1 "Pfizer"))
                :op2 (z7 / company
                         :name (z8 / name
                                   :op1 "BioNTech"))))
Pfizer / BioNTech is a nbiggerty thing
z5 :name z6
z6 :op1 1
z4 :op1 z5
z4 :op2 z7
z7 :name z8
z8 :op1 0
z1 :ARG2 z2
z1 :ARG3 z3
z0 :ARG1-of z1
z0 :domain z4